Trial Profile
Open Label Study of Single Dose Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy.
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2022
Price :
$35
*
At a glance
- Drugs Rhenium 188 P 2045 (Primary)
- Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer; Small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Andarix Pharmaceuticals; Bayer; Bayer HealthCare Pharmaceuticals Inc.
- 31 Oct 2022 Status changed to recruiting.
- 31 Oct 2022 Planned End Date changed from 1 Apr 2020 to 20 Apr 2025.
- 29 May 2009 New trial record